Joe Rogan Experience #1661 - Rick Doblin

MDMA Dosing

Rick Doblin, founder of MAPS, discusses the complexities of determining effective MDMA dosages for therapeutic use. He explains that while 125 milligrams was initially considered the effective dose, studies revealed that 75 milligrams could be equally beneficial, especially for veterans, firefighters, and police officers. This discovery challenges previous assumptions and highlights the importance of finding a balance between therapeutic efficacy and patient comfort.

The goal is to try to do double blind studies, randomized, placebo controlled double blind studies, so people don't know what dose they're getting.

--- Rick Doblin

Doblin emphasizes the need for precise dosing to ensure patients are in the optimal arousal zone, where they can process trauma effectively without being overwhelmed 1 2.

   

Trauma Healing

MDMA therapy has shown promising results in treating PTSD, with significant symptom reduction in many patients. Doblin highlights that in phase two studies, 56% of participants no longer had PTSD after two months, and this number increased to two-thirds after a year. This suggests that MDMA therapy not only provides immediate relief but also facilitates long-term healing by allowing patients to process trauma deeply.

People can keep getting better on their own without more drugs.

--- Rick Doblin

The therapy's success is attributed to its ability to help patients confront and process their trauma, contrasting with traditional treatments that often only manage symptoms 3 4.

   

Scalability

Scaling MDMA therapy presents challenges, particularly in training enough therapists and navigating regulatory hurdles. Doblin notes that MAPS has invested millions in research and training, aiming to prepare thousands of therapists to meet the growing demand. However, the therapy's success depends on both therapist availability and insurance coverage, which are crucial for making it accessible to a broader audience.

We want to get tens and tens, tens of thousands of therapists for all these thousands of psychedelic clinics.

--- Rick Doblin

Efforts are underway to expand MDMA therapy globally, with initiatives in countries like Israel and Canada, but regulatory and logistical challenges remain significant 5 6.

   

Future Prospects

The future of MDMA therapy looks promising as it moves towards mainstream acceptance, with significant progress in regulatory approvals. Doblin shares that MAPS has successfully challenged FDA requirements, allowing for more flexible therapist training protocols. This victory is crucial for reducing therapy costs and increasing accessibility.

We won this formal dispute resolution.

--- Rick Doblin

Looking ahead, Doblin envisions a future where MDMA and other psychedelics are integrated into therapeutic practices worldwide, potentially leading to licensed legalization by 2035 7 8.